Archives: Premium Distribution

• FingerMotion received approval for its application for Nasdaq up-listing, and commenced trading on Tuesday, December 28, 2021, under the company’s current trading symbol, “FNGR”
• The approval marks a key milestone for the company as it plans to execute an ambitious growth strategy for the 2022 calendar year
• It marks FingerMotion’s second successful up-listing application with the first one (for the OTCQB Venture Marketplace) having gone through back in February 2019

FingerMotion (NASDAQ: FNGR) just announced listing its shares of common stocks on The Nasdaq Stock Market LLC (“Nasdaq”). The approval, which came on December 27, 2021, has seen FingerMotion become the latest technology company listed on the Nasdaq Capital Market, a move that offers the company great exposure within the investment community (https://ibn.fm/J8qfA).

FingerMotion’s listing marks a significant milestone, particularly as it seeks to execute its ambitious growth strategy for…

Read More>>

About ChineseWire

ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.

For more information, please visit https://www.ChineseWire.com

Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer

ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
[email protected]

ChineseWire is part of the InvestorBrandNetwork.

The race to complete electrification is heating up. While electric vehicle (“EV”) startups such as Tesla showed the world that it was possible to mass produce zero-emission electric cars, the nascent EV market is now seeing an influx of competition from startups such as Rivian Automotive Inc. (NASDAQ: RIVN) as well as established carmakers. Rivian recently went public in one of the largest IPOs in history and achieved a valuation of more than $100 billion. The California-based electric truck maker is now working on its first electric offerings, including the electric Rivian R1T pickup truck, which will hit the market next year.

Several states are hoping to lure these EV startups and automakers as manufacturing facilities can provide plenty of new jobs and raise the economic status of surrounding companies. It looks as if Rivian, which was the first EV company to market an electric pickup truck, is in high demand. The state of Georgia may soon put together an incentive package that will be the largest ever in state history…

Read More >>

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

• Flora Growth Corp. is a Canadian cannabis and wellness brand distributor operating from a cultivation base in central Colombia
• The company’s focus on sustainability guides its efforts to market products that are beneficial to their local communities as well as the world at large
• Market analysts predict 2022 will see the global CBD skin care market segment alone grow with a CAGR of 24.8 percent
• The COVID-19 pandemic is continuing to drive expansion of online retail that affects the cosmetics sector as well as clothing, groceries and other avenues that may include the more-than-190 cannabis-derivative products produced by Flora Growth 

Plant-based wellness and lifestyle collective Flora Growth (NASDAQ: FLGC) is entering 2022 with momentum from the past year’s aggressive growth campaign for its global cannabis-derivative brand distribution of pharmaceuticals, cosmetics and nutraceuticals. 

While industry news has largely focused on M&A activity and questions about when the United States may grant federal legalization of cannabidiol (“CBD”) following the advance and then defeat of supportive banking measures in 2021, Canada-based Flora has been completing agreements with partners in numerous countries to expand its verticals from their cultivation origins in central…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

McDonald’s Corporation (NYSE:MCD) traded at a new 12-month high today of $270.73. This new high was reached on below average trading volume as 700,000 shares traded hands, while the average 30-day volume is approximately 2.7 million shares.

Based on a current price of $268.55, McDonald’s Corporation is currently 35.1% above its average consensus analyst price target of $174.16.

McDonald’s is the largest restaurant owner-operator in the world, with trailing 12 month system sales of $109 billion (as of the third quarter of 2021) across 39,680 stores and 119 countries. McDonald’s pioneered the franchise model, building its impressive footprint through partnerships with independent restaurant franchisees around the world. The firm earns nearly 60% of its revenue from franchise royalty fees and lease payments, with the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets. McDonald’s owns 55% of the real estate and 80% of the buildings in its franchise system, offering it substantial leverage in maintaining quality standards and consistency.

In the past 12 months, McDonald’s Corporation share prices are bracketed by a low of $202.73 and a high of $270.73 and are now at $268.55, 32% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Ulta Beauty Inc. (NASDAQ:ULTA) traded today at $419.29, eclipsing its 12-month high. This new high was reached on below average trading volume as 274,000 shares traded hands, while the average 30-day volume is approximately 818,000 shares.

In the past 12 months, Ulta Beauty Inc. share prices are bracketed by a low of $276.00 and a high of $419.29 and are now at $418.95, 52% above that low price.

Ulta Beauty is the largest specialized beauty retailer in the U.S. with approximately 1,300 stores. The firm offers makeup (44% of 2020 sales), fragrances, skincare, and haircare (20% of 2020 sales) products, and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.

Ulta Beauty Inc. defies analysts with a current price ($418.95) 80.5% above its average consensus price target of $81.84.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The Estee Lauder Companies Inc. (NYSE:EL) traded at a new 12-month high today of $374.20. So far today approximately 211,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares.

Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (58% of fiscal 2021 sales), makeup (26%), fragrance (12%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 23% of fiscal 2021 revenue stemming from the Americas, 43% from Europe, the Middle East and Africa, and 34% from Asia-Pacific. The company sells its products through department stores, travel retail, multibrand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.

The Estee Lauder Companies Inc. is currently priced 5.2% above its average consensus analyst price target of $349.77.

In the past 12 months, The Estee Lauder Companies Inc. share prices are bracketed by a low of $231.97 and a high of $374.20 and are now at $369.02, 59% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

If Bloomberg is to be believed, the NYPD may have joined the growing number of police departments across the country that are considering adding electric vehicles (“EVs”) to their fleets. President Joe Biden recently announced via an executive order that the entire federal fleet is to be fully electrified over the next few decades, completely eliminating the purchase of new internal combustion cars by 2035. The order required that every federal agency with at least 20 cars develop a strategy to electrify their fleets and update it annually. Although this order doesn’t include state and city police departments, several of these entities also plan on incorporating EVs into their fleets.

For the New York Police Department, which runs a fleet of 9,000 vehicles, this reportedly involves Teslas. According to a Bloomberg report, the NYPD is mulling over a purchase of 250 Tesla (NASDAQ: TSLA) Model 3s at a cost of $12.36 million. This would come out to around $51,940 for each electric sedan, a copy of the procurement contract states. Bloomberg…

Read More >>

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

PerkinElmer Inc. (NYSE:PKI) traded at a new 12-month high today of $199.57. Approximately 157,000 shares have changed hands today, as compared to an average 30-day volume of 1.1 million shares.

PerkinElmer Inc. share prices have moved between a 12-month high of $199.57 and a 12-month low of $119.95 and are now trading 66% above that low price at $198.91 per share.

PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes prenatal screening and infectious-disease testing, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening to environmental analytical tools.

PerkinElmer Inc. is currently priced 36.7% above its average consensus analyst price target of $125.91.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Johnson Controls International plc (NYSE:JCI) traded at a new 12-month high today of $81.69. So far today approximately 454,000 shares have been exchanged, as compared to an average 30-day volume of 3.2 million shares.

Over the past year, Johnson Controls International plc has traded in a range of $45.55 to $81.69 and is now at $81.09, 78% above that low.

Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security represents another 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.

Johnson Controls International plc is currently priced 0.7% above its average consensus analyst price target of $80.48.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board (“IRB”) approval for its planned DehydraTECH-CBD human hypertension study HYPER-H21-4; the approval was received earlier than anticipated. The study is designed to “de-risk” outcomes prior to the company’s planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease. The six-week study, which is entirely funded through the existing cash resources, is planned to include 60 volunteers, aged 45 to 70, using three 150 mg doses of DehydraTECH-CBD daily for the duration of the study. Dosing is anticipated to begin by April of next year. The study will incorporate a double-blinded, randomized, cross-over design, with a placebo control. The length of the study allows the company to evaluate the impact of DehydraTECH-CBD over time as well as the potential for longer-term health benefits. This study is the most comprehensive undertaken by Lexaria. “The hypertension market is valued at $28 billion per year and is expected to continue growing as one of the world’s top health problems and as a subset of the larger heart disease market,” the company stated in the press release. “Over 1.1 billion people worldwide suffer from hypertension. Fewer than 1 person in 4 with hypertension have successfully controlled their blood pressure through medications, meaning the potential market for hypertension drugs is much larger than $28 billion per year if an affordable drug was available with few or no side effects. Lexaria believes that its DehydraTECH-CBD may introduce a more tolerable anti-hypertensive treatment option that may be used alone or in combination with other medications, to reduce BP with fewer discouraging and unwanted side effects.”

To view the full press release, visit https://cnw.fm/MTb6N

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by 5 to 10 times — and in some instances by as much as 27 times — compared to standard industry formulations, as well as reduce time of onset from one to two hours to minutes and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs; nonsteroidal, anti-inflammatory drugs (“NSAIDs”); PDE5 inhibitors; and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX 

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and General Manager of BayMedica, Shane Johnson, and VP of Commercial Operations Chris Meiering will present at Tribe Public’s upcoming webinar presentation and Q&A event. The event, titled “Addressing the Increasing Demand for Rare Cannabinoids,” is slated to begin at 8 a.m. Pacific/11.a.m. Eastern on Jan. 6, 2022. Interested parties should visit https://ibn.fm/Qxj0G to register to join the complimentary, ZOOM webinar-based event. Once registered, participants may begin forwarding their questions for InMed and BayMedica’s management to Tribe Public at [email protected] or share their questions via the ZOOM chat feature during the event.

To view the full press release, visit https://ibn.fm/ZxioZ

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, has recently announced that it will no longer have to consolidate the financials of its former subsidiary, BIGtoken Inc. Following the successful spin-off of BIGtoken, SRAX’s core operations will be centered around Sequire, which has grown to over 9 million followers whilst simultaneously seeing its number of subscribers swell to 250 public companies. “Sequire has witnessed the company’s growth trajectory rise from strength to strength, with the company recently announcing the launch of its new IR website builder, SMS communication platform, and VIRA, an IR-powered chatbot,” reads a recent article. “SRAX and Sequire have also sought to provide additional value-added services to its legions of subscribers and followers by hosting the recent flagship and in-person LD Micro Event, which attracted over 750 in-person attendees and 12,000 virtual attendees.”

To view the full article, visit https://ibn.fm/aB77q

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is repurchasing up to 2 million company shares. The company announced that its board of directors had approved the move, which allows the company to purchase the shares over the next year at prevailing market prices. The repurchasing plan, which begins on Jan. 4, 2022, and ends on Dec. 30, 2022 (unless the company ends the program earlier), allows FSD Pharma to use its excess cash reserves to strategically return value to shareholders. The plan calls for the company to purchase up to 2 million subordinate voting shares, which is approximately 5% of the company’s issued and outstanding subordinate voting shares. “FSD Pharma is focused on the advancement of its drug candidates toward the clinic,” said FSD Pharma interim CEO Anthony Durkacz in the press release. “However, with over $39.3 million in cash and cash equivalents on our balance sheet as of Sept. 30, 2021, we recognize there may be a strategic opportunity to enhance shareholder value without compromising our ambitious growth plans. We believe that our stock is significantly undervalued. This will allow us to continue investing in our future, while, at the same time, also investing in the exceptional value that our own shares represent.”

To view the full press releases, visit https://ibn.fm/bn4k2

About FSD Pharma Inc.

FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA, formerly called FSD-201. Lucid Psycheceuticals Inc. is a wholly owned subsidiary focused on the research and development of FSD Pharma’s lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information about the company, please visit www.FSDPharma.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Shares of Essential Utilities Inc. (NYSE:WTRG) traded at a new 12-month high today of $53.20. So far today approximately 164,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares.

Based on a current price of $53.20, Essential Utilities Inc. is currently 32.6% above its average consensus analyst price target of $35.84.

Essential Utilities is a Pennsylvania-based holding company for U.S. water, wastewater, and natural gas distribution utilities. The company’s water business serves 3 million people in eight states. Nearly three fourths of its water earnings come from Pennsylvania, primarily suburban Philadelphia. It also has a small market-based water business that provides water and water services to third parties, notably natural gas producers. Its $4.3 billion Peoples Gas acquisition that closed in March 2020 adds 750,000 gas distribution customers in Pennsylvania, West Virginia, and Kentucky.

In the past 12 months, shares of Essential Utilities Inc. have traded between a low of $41.11 and a high of $53.20 and are now at $53.20, which is 29% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Stag Industrial Inc. (NYSE:STAG) traded today at a new 12-month high of $47.50. Approximately 150,000 shares have changed hands today, as compared to an average 30-day volume of 1.3 million shares.

Stag Industrial Inc. has potential upside of 2.9% based on a current price of $47.46 and analysts’ consensus price target of $48.84.

Stag Industrial Inc. share prices have moved between a 12-month high of $47.50 and a 12-month low of $29.40 and are now trading 61% above that low price at $47.46 per share.

Stag Industrial Inc. is a real estate investment trust primarily involved in the acquisition and operation of single-tenant industrial properties throughout the United States. The vast majority of the company’s real estate portfolio is comprised of warehouse and distribution buildings. Most of these facilities are located in Midwestern and Eastern U.S. states. Stag Industrial derives nearly all of its income in the form of rental income from its portfolio of warehouse and distribution properties. The company generates most of its rental revenue from its facilities located in Midwestern and Eastern U.S. cities. Stag Industrial’s largest customers include air freight and logistics, automotive, and industrial equipment companies in terms of overall revenue.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Sprouts Farmers Market Inc. (NASDAQ:SFM) traded at a new 12-month high today of $30.26. This new high was reached on below average trading volume as 315,000 shares traded hands, while the average 30-day volume is approximately 1.9 million shares.

Sprouts Farmers Market is an American specialty grocer offering a health-oriented assortment that focuses on fresh and naturally derived products. Its offerings are especially focused on produce, which constituted around 22% of sales in fiscal 2020. Founded in 2002, the chain is most heavily concentrated in California, which accounted for over one third of its 362 stores as of the end of fiscal 2020. All of the company’s operations are in the United States, with its stores largely located in the southern half of the country. The firm sells roughly 20,000 products (of which nearly 25% are organic), with private-label products accounting for about 16% of sales in fiscal 2020. Perishable items accounted for 57% of fiscal 2020 sales.

Sprouts Farmers Market Inc. has potential upside of 0.8% based on a current price of $30.26 and analysts’ consensus price target of $30.50.

Over the past year, Sprouts Farmers Market Inc. has traded in a range of $19.13 to $30.26 and is now at $30.26, 58% above that low.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. Since its founding in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved to create wearable technologies and digital health care solutions that encourage and empower people to take charge of their health and well-being. “The company’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible continuous glucose monitor (‘CGM’) designed to help people with diabetes and prediabetes manage their glucose levels,” reads a recent article. “The company has recently followed up with the release of the MiBoKo application. This service, which has been in development for the past 18 months, seeks to address a significant mass-market opportunity, which the company believes could benefit roughly a third to half of the global population. The MiBoKo application uses a non-invasive glucose sensor to measure and monitor the user’s metabolic health scores, which are based on glucose tolerance or insulin resistance. Prediabetic patients, those facing obesity concerns, or individuals looking to monitor their glucose intake would all benefit from this application.”

To view the full article, visit https://ibn.fm/1aI1g

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a Premarket Approval Application (“PMA”) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating report for Q2 2021, with notable company milestones and achievements highlighted. The company plans to move through the ongoing remaining preclinical studies for its CYB003 novel deuterated psilocybin analog and submit an investigational new drug application and clinical trial application in the second quarter of 2022 in the U.S. and the U.K., respectively. “Other notable company achievements during the quarter include the U.S. Drug Enforcement Agency’s approval of a Schedule I manufacturing license for Cybin’s research lab, which is located in Boston… The company also received FDA approval for its IND application to proceed with a feasibility study using Kernel Flow quantitative neuroimaging technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. In addition, Cybin launched a first-of-its-kind psychedelic facilitator training program based on EMBARK, a groundbreaking psychotherapy model,” reads a recent article. “The first half of the year has been a transformative period for Cybin that included significant and swift advancements in our research and development pipeline and overall business,” said Cybin CEO Doug Drysdale.

To view the full article, visit https://ibn.fm/3WXKM

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced a key partnership with DSA Systems, a leading international provider of vehicle system diagnostics and remote OTA technology. The partnership calls for the two companies to collaborate on Mullen’s strategic FIVE EV Crossover Program. MULN is working on its Mullen FIVE offering, which is built on an EV crossover skateboard platform that provides multiple powertrain configurations and trim levels in a design that is Strikingly Different(TM). In the announcement, MULN noted that DSA is a global leader in equipping automotive OEMs with vehicle diagnostics and connectivity, building a renowned reputation for providing monitoring and supporting technologies throughout the entire life cycle of vehicles. The company anticipates using DSA’s underpinning diagnostic technology in all future vehicle programs. “We intend for the Mullen FIVE to have the best 5G OTA technology from DSA, allowing us to remotely diagnose and proactively fix potential vehicle issues,” said Mullen Automotive CEO and chair David Michery in the press release. “OTA updates and fixes promote a greater service experience for customers. Ideally, we will be able to proactively identify a potential vehicle issue, remotely update and fix the issue, all while the vehicle is parked at the customer’s home and not a dealership waiting for service.”

To view the full press release, visit https://ibn.fm/yo3LE

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

• Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating hypertension (high blood pressure)
• The company has completed multiple studies of the benefits of DehydraTECH(TM), in combination with cannabidiol to combat hypertension conditions and consequentially benefit cardiovascular patients
• Lexaria recently announced that it is nearing completion of a third human study in which the company expects to further explore whether DehydraTECH-CBD successfully treats high pulmonary blood pressure
• A comprehensive six-week human clinical study is expected to begin soon

Lexaria Bioscience (NASDAQ: LEXX) is nearing completion of a human clinical study it believes will further its claims that its patented DehydraTECH(TM) technology works effectively with cannabidiol (“CBD”) as a potential treatment for hypertension, which has further potential implications for cardiovascular disease patients. Lexaria’s DehydraTECH technology works with drug substances which are orally ingested and enhances how they are processed into the blood stream without adverse consequences from the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office [email protected]

• Flora Growth recently expanded into Mexico and Spain with its Mind Naturals and Awe CBD skincare brands
• Additionally, the company ventured into the dry herb market through Vessel brand, its wholly owned subsidiary
• The recent licensing agreement with Tonino Lamborghini marks Flora Growth’s aggressive product diversification plan that has defined its 2021 calendar year
• All the decisions and moves made by the company so far have been geared toward growing the company’s market share, expanding its market reach, and increasing value for its shareholders

Flora Growth (NASDAQ: FLGC) completed its first traditional cannabis Initial Public Offering (“IPO”) in May 2021. Within seven months, the company has embarked on an aggressive market expansion and product diversification plan geared toward stamping its position within the cannabis brand space and creating value for its shareholders. Its latest move was expanding into Mexico and Spain with its Mind Naturals and Awe CBD skincare brands (https://cnw.fm/GZRvY). These products, targeted toward younger consumers and the prestige market respectively, incorporate present-day consumers’ expectations by… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office [email protected] CBDWire is part of the InvestorBrandNetwork.

• New tech has potential to reduce costs of production, energy consumption and greenhouse gas emissions
• MOU key step in building a new, environmentally friendly REE supply chain in the United States
• Two companies to create a new entity that will hold exclusive license to the technology as it specifically relates to REE metal making

Energy Fuels (NYSE American: UUUU) (TSX: EFR) is partnering with Nanoscale Powders LLC (“NSP”) with plans to develop a novel technology for the production of rare earth elements (“REE”) metals (https://ibn.fm/FO5x2). In the announcement, Energy Fuels noted that the Nanoscale’s patented rare earth metal-making technology has potential to revolutionize the rare earth metal space. “We believe this technology, which was initially developed by NSP, and will be advanced by the company and NSP working together, has the potential to revolutionize the rare earth metal making industry by reducing costs of production, reducing energy consumption, and… Read More>> NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU About Green Energy Stocks Green Energy Stocks (GES) is a specialized communications platform with a focus on companies working to shape the future of the green economy. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the InvestorBrandNetwork (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled visibility, recognition and brand awareness. GES is where news, content and information converge. To receive SMS text alerts from Green Energy Stocks, text “Green” to 21000 (U.S. Mobile Phones Only) For more information, please visit https://www.GreenNRGStocks.com Please see full terms of use and disclaimers on the Green Energy Stocks website applicable to all content provided by GES, wherever published or re-published: https://www.GreenNRGStocks.com/Disclaimer Green Energy Stocks Los Angeles, CA www.GreenNRGStocks.com 415.949.5050 Office [email protected] Green Energy Stocks is part of the InvestorBrandNetwork.

• SRAX’s Sequire SaaS platform, and popular investors and industry conferences, provide unique opportunities for investors and public companies to connect and communicate
• The 2021 Sequire Clean Tech & Electric Vehicles Conference was held on December 6th, featuring panels, keynote speakers, and corporate presentations from some of the cleantech industries brightest minds
• Investors can still access the complete conference via the conference website

Without question, everyone today is looking for an investment edge. Investors crave transparency and succinct, actionable insight into genuine growth opportunities. Companies are on a relentless quest to better understand and communicate with their shareholders, as well as the broad investment community. The evolution of the digital world we live in today has simultaneously made things easier and more difficult for both sides of the investment paradigm. That’s where fintech SRAX (NASDAQ: SRAX) comes in to make the opaque clear, providing its Sequire Software-as-a-Service (SaaS) platform for public companies, as well as preeminent conferences where investors can follow favorite companies and meet others that they may have been unfamiliar with. Sequire is a big data analytics platform that allows public companies the ability to track the buying and selling activity of its investors, subsequently using the information to engage its investor base across different marketing channels. The platform gives management a clear view of… Read More>> NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Bit Digital Inc. (NASDAQ: BTBT), a Bitcoin mining company headquartered in New York, has  reported its unaudited financial results for Q3, the period ending Sept. 30, 2021. Included in the report are several notable highlights, including revenue from Bitcoin mining for the period reaching $10.4 million with a total of 248.4 Bitcoins mined; the company noted that number was down from the second quarter because of miner migration and fleet repositioning. Non-GAAP income from operations for the quarter was $4.8 million, with non-GAAP net income coming in at $4 million and cash and cash equivalents totaling $26.5 million and total liquidity, or cash and digital assets, of approximately $61.5 million. “We had no miners remaining in China,” Bit Digital stated in the press release, noting that “100% of our miner fleet was deployed, in transit to, or awaiting installation in North America.” To view the full press release, visit https://ibn.fm/Y9jgF About Bit Digital Inc. Bit Digital is a Bitcoin mining company headquartered in New York City. The company’s mining operations are located in North America. For additional information about this company, visit www.Bit-Digital.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) recently signed a licensing agreement with Tonino Lamborghini that marked Flora Growth’s entry into the cannabis beverages market. Under the terms of the partnership, FLGC will produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia. The product line, which will be produced in Florida for initial sale in U.S. states where cannabidiol (“CBD”) ingestibles are legal, will contain CBD and other premium cannabinoids, including cannabigerol (“CBG”). Tonino Lamborghini is a luxury brand operating in the high-end designer products, hotel, beverage and real estate segments. “We are excited to partner with such a well-known luxury brand as Tonino Lamborghini, which already boasts a very successful line of beverages and aligns with Flora’s portfolio of high-end products,” a recent article quotes Flora Growth CEO Luis Merchan as saying. “This partnership is yet another step in the execution of Flora’s strategic plan to build a world-class house of brands and is also a major component of our sales and distribution strategy in the lucrative U.S. market.”

To view the full article, visit https://cnw.fm/kwFSo

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

• Report forecasts demand for uranium fuel seeing consistent growth
• Increased demand fueled by nuclear energy playing an even larger role in the electricity and energy systems of tomorrow
• As the largest U.S. uranium producer, Energy Fuels holds three of America’s key uranium production centers

The World Nuclear Association’s Annual Nuclear Fuel Report projects that the demand for uranium fuel is set to increase over the next two decades (https://ibn.fm/XNptT). That’s good news for Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading U.S. uranium mining company. “World nuclear generating capacity is set to continue its upward trend with demand for uranium fuel increasing over the period to 2040, according to the projections in the latest edition of World Nuclear Association’s Nuclear Fuel Report,” stated a… Read More>> NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU About MiningNewsWire  MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge. To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only) For more information, please visit https://www.MiningNewsWire.com Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer MiningNewsWire Los Angeles, California www.MiningNewsWire.com 310.299.1717 Office [email protected] MiningNewsWire is part of the InvestorBrandNetwork.  

For the longest time, Toyota Motor’s (NYSE: TM) only electrified cars have been hybrids such as the Toyota Prius hybrid, first launched in October 1997. But while fellow automakers and electric vehicle (“EV”) startups have developed a variety of pure battery-electric vehicles (“BEVs”) and unveiled plans to produce even more EV models over the next decade, the Japanese automaker has dragged its feet in comparison. However, Toyota recently announced that it is finally wading into the battery electric vehicle segment and significantly increasing its EV lineup.

The automaker plans on investing a whopping $70 billion on electrification over the next decade, CEO Akio Toyoda says, with one-half of it going to battery electric vehicle development. This massive investment would see Toyota, currently one of the largest automakers on the globe, build 30 new battery-powered electric cars by 2030. Toyota also wants to ramp up global battery electric vehicle sales until…

Read More >>

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid-MS, the company’s lead drug candidate for the potential treatment of multiple sclerosis (“MS”), in the animal models of MS. “Lucid-MS has demonstrated the potential to prevent the degradation and help re-establish myelin, which is evidenced by the functional recovery of mice as well as immunohistochemistry in this study, and several other studies in preclinical animal models,” said Dr. Lakshmi P. Kotra, Ph.D., CEO of Lucid Psycheceuticals Inc., FSD Pharma’s wholly owned subsidiary. “This effect holds good promise for further development as a potential treatment for MS, and the biochemical mechanism of Lucid-MS represents a potential industry first in treating MS. We are eager to advance Lucid-MS to the clinic as quickly as we can.”

To view the full press release, visit https://ibn.fm/kQWtc

About FSD Pharma Inc.

FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc. is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Through its wholly owned subsidiary, Lucid, the company is also focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information, visit the company’s website at www.FSDPharma.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has formed a regulatory advisory board (“RAB”) and has appointed Joga Gobburu, B.Pharm (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members. Dr. Gobburu is a world-recognized scientific leader in pharmacometrics and a professor at the School of Pharmacy and the School of Medicine at the University of Maryland. Dr. Melnyk is an expert in manufacturing and regulatory requirements for pharmaceutical and medical device development. She is the senior regulatory consultant at Innovalinks, a consulting firm serving the pharmaceutical industry in the quality and regulatory systems, process transfer, and validation and scale-up. The RAB was formed by Dr. Lakshmi P. Kotra, B.Pharm (Hons), Ph.D., CEO of FSD Pharma’s wholly owned subsidiary, Lucid Psycheceuticals Inc. “We are thrilled to welcome Drs. Gobburu and Melnyk as members of our recently established board and are looking forward to applying their combined expertise in global quality and regulatory systems as we advance our drug candidates toward the clinic to serve global markets,” Dr. Kotra said in the news release.

To view the full press release, visit https://ibn.fm/OZwCk

About FSD Pharma Inc.

FSD Pharma is a life sciences holding company with two wholly owned subsidiaries dedicated to building a portfolio of diversified therapeutic assets and innovative health care and biotech services. FSD BioSciences Inc., a wholly owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing applications of its lead compound, ultramicronized PEA, by down-regulating the cytokines to effectuate an anti-inflammatory response. Lucid Psycheceuticals Inc., a wholly owned subsidiary, has exclusive worldwide rights to novel compounds shown to prevent and potentially reverse the biochemical mechanisms of progressive multiple sclerosis in multiple preclinical animal models. Additionally, FSD is seeking to develop a unique psychoactive (psychedelic-based) therapeutic aimed at addressing neurodegenerative disorders, a multibillion-dollar mental health market. The company hopes to quickly advance its lead drug candidates through clinical trials. For more information, visit the company’s website at www.FSDPharma.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

SRAX (NASDAQ: SRAX) is a diversified financial technology, digital marketing and consumer data management company that provides an array of consumer data to its clients, valuable to marketing and communications. Its flagship offering is a premier investor intelligence and communications platform branded Sequire. SRAX also recently launched an IR Website Builder, SMS feature and VIRA, and an IR chatbot, expanding its offering and translating to a strong increase in revenue. “SRAX’s technology unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing,” reads a recent article. Sino American Oil Company (OTC: OILY) recently engaged SRAX to better understand its investors and target them in a more efficient manner. The partnership will allow Sino American Oil to optimize marketing and communications strategies to reach out to consumers, shareholders and investors. “According to Sino American Oil CEO Kim Halvorson, the company did its due diligence before partnering with SRAX. ‘We have been following SRAX for some time now, their expertise in the Oil and Gas sector and digital marketing has been impressive,’ said Halvorson.” To view the full article, visit https://ibn.fm/BQcXk About SRAX Inc. SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

• In a recent human clinical trial, HYPER-H21-2, DehydraTECH™-CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat cardiovascular and other diseases beyond hypertension
• Lexaria’s patented technology DehydraTECH improves how APIs enter the bloodstream –making multiple benefits possible such as increased delivery speed, increase in brain absorbency, higher bioavailability, and lower costs
• The company has patent protection received for delivery of nicotine, vitamins, NSAIDs, terpenes and cannabinoids; and patents pending for delivery of estrogen, testosterone, PDE5 inhibitors, antiviral drugs and more

Oral absorption is the most convenient and widely used administration route for taking medications. Decades of research have advanced the understanding of critical factors – anatomical, physiological, and drug information – which control oral bioavailability. Scientists are now better understanding the physiological function and formulation functionality that has been used in designing better and more desirable oral medicine delivery through extensive research. Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, is accomplishing this through its patented DehydraTECH(TM) technology. DehydraTECH(TM) improves the way that active pharmaceutical ingredients (“APIs”) make their way into the bloodstream. This is achieved by promoting healthier ingestion methods and an increase in the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office [email protected]

• Nemaura Medical announced the successful completion of its initial shipment of sugarBEAT(R) continuous glucose monitor devices to its UK licensee
• The initial shipment, which comprised 5,000 CGM devices and 200,000 sensors, is expected to result in follow-on monthly orders of up to 2 million sensors and 15,000 CGM devices over the next two years
• Following the launch of the sugarBeat(R), Nemaura Medical have released the MiBoKo application, designed to help individuals track their metabolic health scores

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, revealed that it had recently completed its initial shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its UK licensee, MySugarWatch Limited (“MySugarWatch”), previously known as DB Ethitronix Limited (https://ibn.fm/D3B2b). MySugarWatch will market the sugarBEAT product under the MySugarWatch(R) brand and has developed a subscription-based diabetes coaching and management service packaged alongside the sugarBEAT monitor and related device sensors, an offering directed towards individuals diagnosed with… Read More>> NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Excellon Resources (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) today announced the filing of an independent technical report for the Silver City Project in Saxony Germany, which was prepared in accordance with National Instrument 43-101. A copy of the technical report is available on SEDAR at www.sedar.com and via the company’s website. According to the update, the author of the technical report, Michael J. Robertson, Pr.Sci.Nat (400005/92); MAusIMM (316078), of the independent consulting firm The MSeA Group (Pty) Ltd., has concluded that Excellon’s proposed exploration program is appropriate for the Silver City Project.

To view the full press release, visit https://ibn.fm/9fziL

About Excellon Resources Inc.

Excellon’s vision is to create wealth by realizing strategic opportunities through discipline and innovation for the benefit of its employees, communities and shareholders. The company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality advanced exploration gold project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration. The company also aims to continue capitalizing on current market conditions by acquiring undervalued projects. Additional details on Excellon’s properties are available at www.ExcellonResources.com.

NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
[email protected]

MiningNewsWire is part of the InvestorBrandNetwork.

SRAX (NASDAQ: SRAX) is a diversified financial technology, digital marketing and consumer data management company that provides an array of consumer data to its clients, valuable to marketing and communications. Its flagship offering is a premier investor intelligence and communications platform branded Sequire. SRAX also recently launched an IR Website Builder, SMS feature and VIRA, and an IR chatbot, expanding its offering and translating to a strong increase in revenue. “SRAX’s technology unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing,” reads a recent article. Sino American Oil Company (OTC: OILY) recently engaged SRAX to better understand its investors and target them in a more efficient manner. The partnership will allow Sino American Oil to optimize marketing and communications strategies to reach out to consumers, shareholders and investors. “According to Sino American Oil CEO Kim Halvorson, the company did its due diligence before partnering with SRAX. ‘We have been following SRAX for some time now, their expertise in the Oil and Gas sector and digital marketing has been impressive,’ said Halvorson.” To view the full article, visit https://ibn.fm/BQcXk About SRAX Inc. SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has provided a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the company for a transformative 2022. “2021 was an exciting year for Cybin. We expanded our organization from five to more than 55 employees across four countries and have established an operating ecosystem of nearly 50 partners and vendors that have supported more than 90 preclinical studies and numerous patent and investigational new drug filings over the past 12 months,” said Cybin’s CEO Doug Drysdale in the news release. “Driven by promising and differentiating preclinical data, our innovative operational and R&D pipeline platforms expect to support four first-in-human clinical studies in 2022, which we hope will progress our proprietary psychedelic development candidates CYB003 and CYB004 closer toward potential approval for treating depression and addiction disorders. We believe 2022 will be a truly transformative year for Cybin.”

To view the full press release, visit https://ibn.fm/Oe2yL

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Patent filings described herein are held by Cybin IRL Limited, a wholly owned subsidiary of Cybin. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. In January 2022, the company expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies that evidenced effective, sustained and safe blood pressure reduction with DehydraTECH-CBD. The company will also be expecting approvals for the protocols around its fourth hypertension study, HYPER-H21-4, which is just one of the many planned studies slated for 2022. “Others include HOR-A22-1, a pharmacokinetic study to evaluate DehydraTECH’s ability to improve the delivery characteristics of estrogen; DEM-A22-1, an efficacy modeling study to evaluate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia; RHEUM-A22-1, an efficacy modeling study to investigate the ability of DehydraTECH-CBD to potentially affect the treatment of rheumatoid disease; and DIAB-A22-1, an efficacy modeling study to explore DehydraTECH-CBD’s ability to potentially impact treatment of diabetes,” explains a recent article. “In addition to fulfilling Lexaria’s goal to enter into new, different multibillion markets, the four animal studies will mark the company’s push to help patients living with these conditions, some of which are potentially fatal.”

To view the full article, visit https://cnw.fm/93Tti

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Electrification is picking up more steam as countries pass increasingly strict tailpipe emission standards and more players join the nascent electric vehicle (“EV”) industry. Furthermore, the electric vehicle game isn’t limited to just EV startups; most established automakers are also working on electrifying their vehicle lineups and surpassing Tesla, which is currently the world’s largest electric vehicle maker. General Motors Company (NYSE: GM) plans to achieve this goal in large by leveraging existing manufacturing facilities and retrofitting them to build electric vehicles. And like fellow automakers, GM will invest a significant amount of money in electrification in the next decade.

According to sources close to the Detroit-based carmaker, GM intends to invest more than $3 billion to manufacture electric vehicles in its home…

Read More >>

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Electric vehicles have one core aspect that makes them extremely superior to combustion engine vehicles: they produce zero emissions at the tailpipe. By eliminating combustion engines and the fossil fuels that power those engines in exchange for rechargeable battery packs, automakers can reduce vehicle emissions by a significant margin. With a large portion of the world looking to cut down greenhouse gas emissions in a bid to arrest runaway climate change, EVs represent the next logical evolution of vehicular transport. However, EV technology is still relatively new, and players in the EV and battery-making spaces are constantly tweaking their formulas and designs to create more energy-dense EV batteries and energy-efficient electric cars.

That’s what makes a recent announcement by California-based EV startup Tesla Inc. (NASDAQ: TSLA) so interesting. In late August, the EV pioneer announced that it was offering an alternate version of the Model 3 Standard Range+ that would allow customers who had preordered the EV to get it sooner. By incorporating new battery chemistry into the Model 3 cars, Tesla could deliver the vehicles…

Read More >>

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, held its general meeting on Dec. 17, 2021, and approved the election of all director nominees. Those elected will hold office until the next annual shareholder meeting or until their successors are elected or appointed. The company also noted that all of the matters outlined for consideration and approval in InMed’s notice of meeting and management information circular were approved. In addition, the company announced that an article discussing cannabinol (“CBN”) as a potential treatment option for glaucoma has been published in a peer-reviewed journal. The article, titled “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma,” was published in the “Biochimica et Biophysical Acta” journal. The article concludes that, first, CBN may promote neuroprotection of cells in the retina that are responsible for vision, and second, the substance may normalize intraocular pressure by attenuating changes in the extracellular matrix proteins. “Having this research peer-reviewed and published in such a reputable journal is a significant milestone for InMed’s glaucoma development program,” said InMed scientific advisor Dr. Mauro Maccarrone in the press release. “This provides important external validation for the scientific community as the program advances towards human studies. We believe InMed’s INM-088 program has significant implications for neuroprotection within the glaucoma space and may lead to a potential new treatment for millions of people suffering from this condition worldwide.”

To view the full press releases, visit https://ibn.fm/OSBUi and https://ibn.fm/7n2wg

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is partnering with Dürr, one of the world’s leading mechanical and plant engineering firms. Durr brings extensive expertise in automation and digitalization to the partnership, which is designed to focus on MULN’s EV manufacturing footprint. According to the agreement, Dürr, which has extensive expertise in automation and digitalization, will support Mullen’s Advanced Manufacturing and Engineering Center (“AMEC”) with full integration for vehicle assembly and complete paint shop technologies; the engineering center is located in Tunica, Mississippi. “Dürr is a leading international manufacturing systems and technology provider for the automotive industry,” said Mullen Automotive CEO and chair David Michery in the press release. “Our Tunica facility will be a leading example of manufacturing automation. Our goal is to have the best and most efficient manufacturing footprint in the U.S., and Dürr is a key partner in achieving this effort.”

To view the full press release, visit https://ibn.fm/feKeA

About Mullen

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

• Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood pressure)
• The company’s studies earlier this year indicated the potential of DehydraTECH to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation
• Arterial stiffness is a noted indicator of diseases such as heart, kidney and pancreas organ ailments that increase mortality with age, therefore the ability to reduce arterial stiffness may have implications for improving human wellness and longevity
• HYPER-H21-2 results evidence DehydraTECH-CBD reduces arterial stiffness

Lexaria Bioscience (NASDAQ: LEXX), an innovator in how drugs are utilized by the human body, is reporting newly found benefits from cannabidiol (“CBD”) enhanced by Lexaria’s patented DehydraTECH(TM) technology. The company’s Dec. 8 news release notes that DehydraTECH-formulated CBD was found to reduce arterial stiffness in mild-to-moderate hypertension (high blood pressure) patients volunteering in Lexaria’s HYPER-H21-2 human clinical study (https://cnw.fm/zIrF2). The company believes… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office [email protected]

Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a psychedelic drug impacts the substance’s effects. Microdosing refers to consuming a small dose of a recreational dose of a psychedelic, the most commonly used substances being psilocybin and LSD.

The biotech firm announced that its research would…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

• Flora Growth’s subsidiary, Vessel Brand, recently introduced new products for dry herb consumption and anticipates releasing additional products in 2022
• FLGC acquired Vessel in a transaction that closed in November
• Founded in 2018, Vessel is an industry leader in the cannabis consumer technology and accessories space
• Flora Growth also announced a 2022 revenue guidance of $35-45 million
• CEO Luis Merchan held a webinar on December 14 in which he highlighted the company’s 2021 operational performance, commented on the revenue guidance, and fielded questions

Flora Growth (NASDAQ: FLGC), an internationally focused company committed to delivering the most compelling customer experiences in the world through its collection of plant-based wellness and lifestyle brands, is building an ecosystem of products that will support market-leading innovation within categories that matter most to consumers exploring plant-based consumer goods. In fulfilling this objective as well as its operational tenet ‘lead by design’, Flora Growth recently announced its wholly owned subsidiary, Vessel Brand, had introduced a robust portfolio of new products for… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office [email protected] CannabisNewsWire is part of the InvestorBrandNetwork.

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, recently published its third-quarter 2021 results. “SRAX reported third-quarter revenues of $8.3 million, a figure which was up 219% year-over-year and 8% on a quarter-on-quarter basis. The company also seized the opportunity to update their corporate revenue guidance, for $10.1 million Q4 revenues, whilst simultaneously re-affirming fiscal year 2021 guidance and raising their target to $31.5 million. SRAX’s stellar third quarter continues a trend that has seen the company’s financial returns go from strength to strength over the past year. The company comfortably met their revised Q3 revenue guidance of $8.3 million, which had been upgraded following the release of Q2 results,” reads a recent article. SRAX also reported third-quarter gross margins of 78%, up from 67% in the same period last year. “SRAX’s earnings announcement comes amidst a period of strong growth for the company. SRAX revealed that their Sequire investor intelligence platform had seen the number of subscribers swell to 250 public companies, a dramatic increase relative to the 225 companies on the platform in the second quarter and up from a mere 92 subscribers as of the Q3 2020 results.”

To view the full article, visit https://ibn.fm/237XZ

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art, signal-processing components for satellite and 5G communications networks, defense, space and other commercial applications, has completed the purchase of the assets and operations of Spectrum Semiconductor Materials Inc. Based in California, Spectrum is a rapidly growing global specialty distributor of semiconductor components. According to AMPG, the transaction should provide significant financial benefits to the company while also adding significant distribution reach. The announcement noted that Spectrum is on track to reach unaudited 2021 revenue $13 million unaudited revenue for 2021. The announcement also observed that Spectrum has an existing powerful distribution platform across the United States, Europe and Asia, which is ideal for AmpliTech’s new line of monolithic, microwave-integrated circuit (“MMIC”) chip designs. “Through the Spectrum acquisition we have substantially increased our revenue base with a well-managed, growing business known for high quality and excellent customer service,” said AmpliTech CEO Fawad Maqbool in the press release. “We expect the transaction will be immediately accretive to our top-and bottom-line financial performance. Spectrum also provides an ideal distribution platform to support the launch and commercialization of our MMIC chip solutions in core end markets of aerospace, defense, automotive and computing. We expect AmpliTech and Spectrum to play a key role in improving the speed and efficiency of 5G cellular networks and medium earth orbit and low earth orbit satellite communications systems around the world.” To view the full press release, visit https://ibn.fm/xi0tU About AmpliTech Group Inc. AmpliTech designs, develops and manufactures state-of-the-art radio frequency (“RF”) components for global satellite communications, telecom (5G and IoT), space, defense and quantum computing markets as well as systems and component-design consulting services. AmpliTech has a 13-plus-year track record of developing high-performance custom solutions to meet the unique needs of some of the largest companies in the global industries that it serves. The company is proud of the unique skills, experience and dedication of its focused team, which enables AMPG to deliver superior solutions, faster time to market, competitive pricing and excellent customer satisfaction and repeat business. For more information about the company, please visit www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”). The award is for CYBN’s patent application related to CYB004, an investigational deuterated psychedelic tryptamine compound developed for the potential treatment of anxiety disorders. According to the announcement, allowed claims under the award also include other forms of deuterated psychedelic tryptamine. This award expands Cybin’s intellectual property portfolio and strengthens the company’s position as leading innovator in developing putative psychedelic compounds. According to the company, CYB004 has the potential to effectively treat anxiety disorders without some of the common side effects associated with current treatments. “The receipt of this Notice of Allowance from the USPTO represents an important milestone in expanding our intellectual property portfolio progressing psychedelics to therapeutics for the countless patients in need, and strongly demonstrates the Company’s dedication to the discovery and development of differentiated psychedelic-based compounds for addressing mental health,” said Cybin CEO Doug Drysdale in the press release. “Once issued, this patent may have the opportunity to cover a broad range of claims supporting our IP in psychedelic medicine and further strengthen our emerging best-in-class position in this evolving industry.”

To view the full press release, visit https://ibn.fm/AsMaV

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Patent filings are held by Cybin IRL Limited, a wholly owned subsidiary of Cybin. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

• Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021
• The event came right after the company announced human clinical hypertension study HYPER-H21-4, its most ambitious one yet
• Lexaria plans to sublicense its patented DehydraTECH(TM) technology worldwide, allowing for more people to benefit from it
• Going into 2022, the company looks forward to reporting on results from its HYPER-H21-3 clinical study and receiving Independent Review Board (“IRB”) approval for its HYPER-H21-4 study

Lexaria Bioscience (NASDAQ: LEXX) just participated in this year’s Benzinga Global Small Cap Conference. The two-day event was a showcase for small cap investing, bringing together shareholders, entrepreneurs, and investors. George Jurcic, the head of Investor Relations (“IR”) at Lexaria, represented the company. He was among 50 other speakers who took the stage in this event that featured 15-minute company presentations… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office [email protected]

Energy Fuels (NYSE American: UUUU) (TSX: EFR) today announced the execution of a memorandum of understanding (“MOU”) with Nanoscale Powders LLC (“NSP”) for the development of an innovative technology for the production of rare earth element (“REE”) metals. “Metal-making is a critical step in the rare earth supply chain. Energy Fuels has already restored monazite ‘crack-and-leach’ capabilities to the U.S. at our White Mesa Mill in Utah, where today we are producing a high-purity mixed rare earth carbonate, which is ready for separation. No other company in the U.S. is currently producing a high-purity REE product ready for separation at commercial levels. We are also quickly moving toward adding solvent extraction separation equipment at the Mill and associated permitting that will allow us to produce commercial separated rare earth oxide powders in the coming years,” said Energy Fuels president and CEO Mark S. Chalmers. “The next step in rare earth processing and refining is turning those separated rare earth oxide powders into usable rare earth metals and alloys, particularly NdPr metal needed for NdFeB magnets used in EVs, wind generation and other technologies. We are interested in Nanoscale Powders’ technology because we believe it has the potential to produce REE metals at lower cost, using less energy, and producing significantly less greenhouse gas emissions than conventional REE metal making methods. If successful, Nanoscale’s metal-making technology could be orders of magnitude safer and less expensive than the current established technology. This is the type of technology we as Americans need to develop to produce advanced rare earth materials in a cost-competitive manner, while achieving the highest standards of protection of public health, safety and the environment. Nanoscale Powders has proven their technology on a small scale, and we look forward to working with them to advance the technology to pilot scale, and then to commercial scale in the coming years. Our relationship with Nanoscale Powders demonstrates Energy Fuels’ commitment to fully integrating a domestic REE processing supply chain in the most optimal and environmentally prudent manner possible.”

To view the full press release, visit https://ibn.fm/Vy3Ey

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and is ramping up to commercial-scale production of REE carbonate. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States . Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate and uranium from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol UUUU, and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol EFR. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
[email protected]

MiningNewsWire is part of the InvestorBrandNetwork.

Nemaura Medical (NASDAQ: NMRD) has developed a platform to monitor multiple chemicals in the blood without needles, replacing traditional invasive methods of diagnosis and health care observations. With the global continuous glucose monitoring (“CGM”) devices market expected to reach $19.04 billion in 2028 from $4.11 billion in 2020, according to an analysis by Reports and Data (https://ibn.fm/UBSIU), key companies in the space, including Nemaura Medical, are ideally positioned to benefit from this growth as they work to meet the needs of the industry. CGM devices enable tracking of blood glucose levels around the clock by monitoring the levels via sensors that send readings to the receiver’s device screen or smartphone. They aid patients in managing diabetes with lesser fingerstick tests. “Nemaura Medical’s proprietary sugarBEAT(R) device is the world’s first-of-its-kind non-invasive continuous glucose monitoring sensor designed for use by ‘everyone,’ meaning people dealing with either type 1 or type 2 diabetes as well as those with prediabetes,” reads a recent article. “The device attaches on (not under) the skin and measures real-time blood glucose levels every five minutes. This invaluable information allows individuals to make adjustments to their diet and activity that can significantly change their lives.”

To view the full article, visit https://ibn.fm/n4EXK

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a Premarket Approval Application (“PMA”) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a preclinical study focusing on CYB003, one of its psilocybin programs. A recent article quotes CEO Doug Drysdale as saying, “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental health care, but few companies have addressed the well-known limitations and side effects of oral psilocybin… Cybin has always strived to develop safer and more effective therapies for patients, which has guided our multiple psilocybin programs: CYB001, CYB001 and CYB003.” The positive CYB003 preclinical findings demonstrate distinctive advantages for its newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. The CYB003 program is designed to maintain the benefits of oral psilocybin, which, according to previous research, appears to be efficacious in treating mental health disorders while addressing associated challenges, including the slow onset of action, extended duration of effect and variability in response among patients.

To view the full article, visit https://ibn.fm/S9VEQ

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC), a company guided by the mission to build a connected, design-led collective of plant-based wellness and lifestyle brands that provide customers with a one-of-a-kind experience, recently announced it had closed the acquisition of Vessel Brand Inc., an industry leader in cannabis consumer technology. “This marks the addition of an exceptional brand builder with a proven track record of not only launching successful cannabis-related brands but also capturing market share in the rapidly-expanding United States cannabis landscape,” reads a recent article. “When making the announcement, Luis Merchan, the president and CEO of Flora Growth, noted, ‘With this acquisition now closed, we can focus on the execution of our combined expansion strategy… The integration of our two organizations is well underway, and the Vessel team is expected to substantially enhance the branding and marketing function of Flora Growth as we look to further increase market share in the global cannabis and wellness markets.’”

To view the full article, visit https://cnw.fm/As8W0

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

• SRAX’s BIGtoken platform announced their merger with BritePool Inc on September 27th, with both entities officially completing their merger on December 2, 2021
• SRAX have simultaneously revealed that they will no longer consolidate BIGtoken’s financials within their financial results
• Post-merger, SRAX’s core operations will focus on investor intelligence SaaS platform, Sequire, which now boasts over 9 million followers and 250 corporate subscribers
• Sequire has forecast to report $16.5 million in 4Q21, an accomplishment which would mark the company’s 12th consecutive quarter of revenue growth

SRAX (NASDAQ: SRAX) a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has recently announced that it will no longer have to consolidate the financials of its former subsidiary, BIGtoken, Inc (https://ibn.fm/ULbBn). BIGtoken, a proprietary consumer insights platform founded and operated by SRAX, Inc, was created with the purpose of enabling the over 16.7 million consumers on their platform to both own and monetize their digital data in an efficient and transparent manner. In turn, the platform’s customers – which… Read More>> NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products by Bidi(R) Vapor LLC, including the BIDI(R) Stick disposable electronic nicotine delivery system (“ENDS”), and Bidi Vapor announced that a recent survey showed  that 80% of adult e-cigarette users and cigarette smokers who responded prefer the BIDI Stick over their current options, including open systems, cartridges/pods and other disposable e-cigarettes. The survey was conducted in the United Kingdom by North Carolina-based research firm Voccii LLC and involved 101 adult users of vaping products and combustible cigarettes and tested preferences between four BIDI Stick flavors with the products that the subjects typically used. Additional survey results indicated that any flavors should do well in the UK (“UK”) market. “While the U.S. e-cigarette market numbers have shown that consumers prefer the BIDI Stick, we are ecstatic to see that the U.K. market research results confirms that the 2% nicotine BIDI Stick is similarly preferred by adult e-cigarette users and smokers in the U.K.,” said Bidi Vapor and Kaival Brands president and CEO Niraj “Raj” Patel in the press release. “From a market perspective, the U.K. has unique regulatory standards that help with direct comparisons between competing devices. For instance, all e-cigarettes must have no more than 2% nicotine levels and tank sizes cannot surpass 2 ml. It’s comforting to know you’re competing on a level playing field.”

To view the full press release, visit https://ibn.fm/k4De7

About Kaival Brands Innovations Group Inc.

Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor. For more information about the company, visit www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced a strategic partnership with ARRK, a leading automotive engineering company based in Munich, Germany. According to the update, ARRK will be supporting Mullen Automotive in Computer Aided Engineering (“CAE”), body in white, battery, closures, interior, chassis, thermal, and infotainment engineering. ARRK will initially support the Mullen FIVE EV Crossover and then move into future vehicles, including a seven-seat SUV program. “ARRK is a leading automotive engineering company with a global footprint, including working with some of the most well-respected automotive manufacturers, such as BMW, VW brands and Mercedes-Benz,” said David Michery, CEO and chairman of Mullen Automotive. “Their vehicle engineering expertise will be a key component for us in hitting our production timeline for the FIVE and beyond.”

To view the full news release, visit https://ibn.fm/jek70

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

• Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022
• The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications
• Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral nicotine delivery

Diabetes, rheumatoid disease, Alzheimer’s Disease, and estrogen delivery, are some of the multiple indications that drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) is planning to target with its research and development programs next year. The markets targeted provide multiple opportunities for success and are now expected to reach an overall estimated value of more than $160 billion annually, worldwide over the next few years. The company will conduct pharmacokinetic and efficacy modelling studies to determine if its patented DehydraTECH(TM) technology can be used successfully to improve delivery of drugs or active pharmaceutical… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office [email protected]

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that its next stop in showcasing the Mullen FIVE EV Crossover, including the debut of level 5 autonomous vehicle technology, will be at the Consumer Electronic Show (CES(R)) in Las Vegas from Jan. 4 – 8, 2022. Mullen will be featured in the Las Vegas Convention Center’s West Hall for the duration of the CES, showcasing the FIVE, including autonomous, powertrain and battery technology. “Our next stop is CES in Las Vegas this coming January. We had tremendous, overwhelmingly positive reaction to the FIVE at the L.A. Auto Show, with many people saying it was the best-looking vehicle at the show and winning the Top SUV EV category, beating out both Rivian and Lincoln,” said David Michery, CEO and chairman of Mullen Automotive. “CES is a one of the best, if not the best, consumer technology event in the world. We are looking forward to starting 2022 in Las Vegas at CES with the Mullen FIVE EV Crossover.”

To view the full news release, visit https://ibn.fm/LQUJY

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, has made available key presentations from its Sequire Clean Tech & Electric Vehicles Conference. The premier virtual investor event was held on Dec. 6, 2021, and featured presentations from more than 25 elite stock market companies that are leading the way in the clean-tech space; the event also included insightful addresses and discussions with industry execs looking at the future of clean tech. Topics covered electric vehicles, energy and power, and materials and chemicals. Replays of the keynote addresses and company presentations are available on the event website for three months. To view the presentations, visit https://ibn.fm/JbYnU To view the full press release, visit https://ibn.fm/IeI9l About SRAX Inc. SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, please visit www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following the acquisition of BayMedica Inc. in October that created an industry leader in the manufacture and commercialization of rare cannabinoids, management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products. In late September, InMed commenced the 755-201-EB study, its phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). A recent article reads, “The commencement of the study marked the first time cannabinol has advanced to a phase 2 clinical trial to be evaluated as a therapeutic option for disease treatment… InMed has also developed a cannabinol (‘CBN’) topical eye drop formulation currently the subject of preclinical studies as a potential treatment for glaucoma… InMed continues to work toward completing the INM-088-based preclinical studies in preparation for human clinical trials. The company anticipates filing regulatory applications in the second half of the 2022 financial year to commence human clinical testing with INM-088.”

To view the full article, visit https://ibn.fm/UY4q0

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed Pharmaceuticals is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Company receives grant to fund clinic for marginalized, underserved NYC communities
• New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service
• Program’s clinicians will receive specialized training

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA). Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East Side of Manhattan, New York. The hospital is… Read More>> NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.PsychedelicNewsWire.com Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW) San Francisco, California www.PsychedelicNewsWire.com 415.949.5050 Office [email protected] PsychedelicNewsWire is part of the InvestorBrandNetwork

• Colombian cannabis cultivator and international wellness product builder Flora Growth Corp. is building a global pipeline for its wide array of branded CBD and medicinal cannabis products
• The company recently announced that it has begun fulfilling the first orders for its Mind Naturals and Awe CBD skincare brands with exports to Spain and Mexico outlets this month
• Flora Growth cultivates cannabis at its 100-hectare (247-acre) property in central Colombia
• Flora also has a GMP certified 16,000-square-foot manufacturing facility in Bogota that produces nearly 200 products for the CBD derivatives and medical cannabis markets

Cannabis cultivator and worldwide cannabidiol (“CBD”) brand builder Flora Growth (NASDAQ: FLGC) continues to expand its consumer product goods and wellness lifestyle technology internationally, recently receiving its first orders for its Mind Naturals and Awe CBD skincare brands from outlets in Spain and Mexico. The company’s e-commerce agreements with SHOWFIELDS and GlossWire’s digital beauty marketplace in October paved the way for the two skincare brands to roll out in international markets. Fulfillment of these initial purchase orders from Amma Spain and Mexico’s… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office [email protected] CBDWire is part of the InvestorBrandNetwork.

BioRestorative Therapies (NASDAQ: BRTX), a life sciences company focused on adult stem cell-based therapies, announced the pricing of the underwritten public offering of 2,300,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock at a per unit price of $10.00. According to the update, the warrants have a per share exercise price of $10.00, are exercisable immediately and expire five years from the date of issuance. As a result of the offering, the company’s common stock began trading under the ticker symbol BRTX on the Nasdaq Capital Market on Nov. 5, 2021. The offering closed on Nov. 9, 2021. In addition, BioRestorative Therapies granted to the underwriters a 45-day option to purchase up to 345,000 additional shares and/or warrants to purchase up to 345,000 shares of common stock to cover over-allotments, if any. Roth Capital Partners acted as sole manager for the offering.

To view the full press release, visit https://ibn.fm/5d3BT

About BioRestorative Therapies Inc.

BioRestorative Therapies develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The company’s two core programs, brtxDISC(TM) and ThermoStem(R), relate to the treatment of disc/spine disease and metabolic disorders. For more information about the company, visit www.BioRestorative.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

• Around 40% of available marketed drugs are poorly bioavailable or soluble, and about 90% of New Chemical Entities are known for their low solubility and permeability
• Lexaria’s patented DehydraTECH(TM) technology offers a solution by improving how APIs (active pharmaceutical ingredients) enter the bloodstream
• DehydraTECH achieves this by bypassing first-pass-liver metabolism
• By doing so, Lexaria is facilitating faster and much more thorough drug delivery

In a report published in the Bioavailability Enhancement Technologies and Services Market, 2018-2030, it was established that around 40% of available marketed drugs are poorly bioavailable or soluble. It was further estimated that approximately 90% of New Chemical Entities (“NCEs”) belong to Biopharmaceutics Classification System (“BCS”) class II and IV, known for their low solubility and permeability (https://cnw.fm/3KzzB). Today, a significant number of drugs fail to reach the market owing to their poor bioavailability. This has prompted companies to re-formulate existing product candidates and explore different tools and… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office [email protected] CannabisNewsWire is part of the InvestorBrandNetwork.

• Charles Schwab survey shows 15% of retail investors started during the COVID-19 pandemic in 2020
• SRAX’s Sequire premier IR communications platform assists public companies understand and communicate with the investment community
• After following SRAX to understand its expertise, Sino American Oil Company has engaged SRAX
• More than 250 companies now use Sequire, driving revenue to $8.3 million in Q3 and on the way to the high-end of 2021 guidance

The coronavirus pandemic changed many things in the world, and you can be sure investing is on the list. According to a Charles Schwab survey earlier this year, about 15 percent of today’s retail investor population got started in 2020, a group Schwab has labeled “Generation Investor.” In the survey of about 1,000 people, Schwab also learned that investing respondents are taking a long approach and that it isn’t just younger generations putting their money in the market, a mix that bodes well for communications specialists like SRAX (NASDAQ: SRAX). SRAX is a diversified financial technology, digital marketing and consumer data management company that provides an array of consumer data to its clients valuable to marketing and communications. SRAX’s flagship offering is a premier investor intelligence and… Read More>> NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, through its wholly owned subsidiary Vessel Brand, has entered the dry herb market. Vessel Brand is expanding into the market with a line of exclusive products, including an all-in-one dry herb smoking kit with an inverted lighter, a premium grinder, an artful ashtray and the company’s own take on the one-hitter with a spiralized interior. A flagship product in the new line of offerings is the Helix, a patent-pending, pure brass device designed to offer the cleanest inhalation possible. Another item grabbing attention is Vessel’s new customizable, “just-add-flower” Eclipse set, which includes the choice of a one-hitter (either the Helix or Vessel’s tapered glass chillum, called Air) as well as a waterproof Basin stash jar and a carbon lighter. New products still slated for release include a functional concrete-and-walnut ashtray made with concrete and real walnut and the new Grinder, a four-piece construction made with precision-engineered aluminum and magnetic closures for easy use. Flora Growth also announced its upcoming earnings webinar, scheduled for Dec. 14, 2021. Flora CEO Luis Merchan will provide an overview of the company’s operational performance during the call, as well as answer questions. “At Vessel, we work tirelessly to set new industry standards and look forward to continuing to deliver on that brand promise within the dry herb market,” said Vessell founder and CEO James Choe in the press release regarding the company’s expansion into the dry herb market. “These new products are just the beginning of what Vessel has in store for consumers across the globe.”

To view the full webinar, visit https://cnw.fm/Tncs9

To view the full press release, visit https://cnw.fm/LIAuO

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

• 1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease
• As many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passing
• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• In addition to sugarBEAT, its flagship device, the company also recently announced the launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores

By 2024, the International Diabetes Federation (“IDF”) predicts that the number of people with diabetes is expected to rise to 1 in 8 adults. Nearly 7 million adults have died worldwide in 2021 so far due to diabetes or its related complications – astoundingly, accounting for over 1 in 10 global deaths from any cause. While enormous, that figure does not consider the lives lost to the novel coronavirus, which has shown to be particularly deadly for people with diabetes. A study found that having Type 1 or Type 2 diabetes tripled the risk of severe illness or death from COVID-19 (https://ibn.fm/laj37). “As many as 40% of the people that have died in the US from COVID-19 had diabetes,” said Dr. Robert Gabbay, chief scientific and medical officer for the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Save Foods (NASDAQ: SVFD), an agri-food-tech company focused on developing and selling eco-friendly products specifically designed to extend the shelf life and ensure food safety of fresh fruits and vegetables, has completed the first commercial sale of its treatment for Medjool dates in the Arava region in Israel, which is the largest exporter of Medjool dates in the world. The sale was completed with Galilee Export, the second largest exporter of fresh produce in the country. This sale comes on the heels of an earlier announcement regarding the company’s first sales in the same region of its treatment for bell peppers. According to the announcement, Galilee Exports will begin broad-scale commercial treatment of its Medjool dates during the upcoming season. Growing and harvesting Medjool dates is more labor intensive than other produce because cannot be picked until they ripen on the trees; other dates ripen after harvesting. Therefore, the cost of harvesting Medjool dates is higher, and Save Foods treatments allow Galilee Exports to maximize the revenues of each harvest, while providing consumers with the highest-quality product, said a Galilee Exports representative. “The benefits of Save Foods’ treatment are recognized on a continuously growing number of produce, Medjool dates being one of them,” said Save Foods CEO Dan Sztybel in the press release. “Our relationship with Galilee Export represents a significant opportunity for the company beyond dates; they have a well-established and growing presence in the global produce market, and a reputation for high-quality produce. I am confident that we will continue to expand our partnership to include new crops and exposure to new markets going forward.” To view the full press release, visit https://ibn.fm/Zix3U About Save Foods Inc. Save Foods is an innovative, dynamic company addressing two of the most significant challenges in the agri-food-tech industry: food waste and loss, and food safety. The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops innovative solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and consumers alike. SVFD’s initial applications are in post-harvest treatments in fruit and vegetable packing houses processing citrus, avocado, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of hazardous chemicals and their residues, Save Foods products not only prolong fresh produce shelf life and reduce food loss and waste, but they also ensure a safe, natural and healthy product. For more information about the company, visit www.SaveFoods.co. NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at https://ibn.fm/SVFD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve delivery of lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (“APIs”) into the bloodstream while speeding onset, increasing bioavailability and improving efficacy. DehydraTECH’s ability to enhance delivery promotes healthier oral ingestion methods and increased effectiveness of fat-soluble active molecules.  As demonstrated through in vivo, in vitro and human clinical testing, DehydraTECH enables fast-acting, less expensive and more effective oral drug delivery. The company operates an in-house research laboratory and has continued to strengthen and broaden its DehydraTECH technology, initially developed in 2014. Lexaria holds an intellectual property portfolio consisting of 23 patents granted in over 40 countries with a combined population of 2.6 billion, as well as over 50 additional patents pending worldwide. Lexaria licenses DehydraTECH to companies around the globe to offer consumers the best possible performance across an array of ingestible products. DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions. The company’s technology offers a delivery method that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effective ness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including for use in industries that produce cannabinoid beverages, edibles and oral products, as well as for a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products. For more information, visit the company’s website at www.LexariaBioscience.com. To learn more about Benzinga’s Small Cap Conference, visit: https://ibn.fm/BenzingaSmallCapDec2021 About InvestorBrandNetwork’s Virtual Coverage The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, provides the online investment community with custom-built portals that include summaries on hundreds of presenting companies. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of various investor conferences. For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer InvestorBrandNetwork (IBN) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office [email protected]

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, has seen a significant rise in its financial returns over the past year. “For the second quarter of fiscal 2021, the company reported Q2 revenues of $7.7 million, up 557% year-over-year, and rising by 41% quarter-on-quarter. The company also seized on the opportunity to update their corporate revenue guidance, increasing Q3 guidance to $8.3 million, which would represent at least a +7.7% quarter-on-quarter increase. SRAX also increased their full year revenue target to $32 million, up from $30 million previously,” reads a recent article. “Immediately following the second quarter earnings report, SRAX announced that they would be carrying out a simultaneous $10 million stock buy-back program as well as paying a one-time special dividend to its shareholders of record as of the 20th of September 2021. The special dividend, which would bear an approximate value of $0.23 per common share, would be in the form of an issuance of non-tradeable preferred shares, which would hold a notional value of approximately $6.5 million worth of Sequire’s clients’ stock. As the underlying shares are sold, the proceeds will be distributed to the preferred shareholders on a periodic basis.”

To view the full article, visit https://ibn.fm/hNOu0

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.